Assessment of i-125 prostate implants by tumor bioeffect

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 5, 2004, Pages 1405-1413

  Haworth, Annette ^a,b   Ebert, Martin ^c,d   Waterhouse, David ^a   Joseph, David ^a   Duchesne, Gillian ^e  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NEWCASTLE MATER HOSPITAL   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Dosimetry; I 125 implants; Prostate cancer; Radiobiology; Tumor control probability

Indexed keywords

TUMOR BIOEFFECTS; TUMOR CONTROL PROBABILITY (TCP);

CELLS; DISEASE CONTROL; DOSIMETRY; IMPLANTS (SURGICAL); RADIOTHERAPY; TUMORS;

ONCOLOGY;

IODINE 125;

ARTICLE; BIOENGINEERING; CANCER RISK; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMPLANT; MATHEMATICAL COMPUTING; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATE IMPLANT; QUANTITATIVE ANALYSIS; RADIATION DOSE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TECHNIQUE; TUMOR CELL; TUMOR LOCALIZATION;

BRACHYTHERAPY; CELL COUNT; HUMANS; IODINE RADIOISOTOPES; MALE; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; PROBABILITY; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 3242662008     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.047     Document Type: Article

References (29)

1. Stock R.G., Stone N., Tabert A., et al. A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108
2. D'Amico A.V., Davis A., Vargas S.O., et al. Defining the implant treatment volume for patients with low risk prostate cancer Does the anterior base need to be treated? Int J Radiat Oncol Biol Phys. 43:1999;587-590
3. McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Am J Surg Pathol. 12:1988;897-906
4. Chen M.E., Johnston D.A., Tang K., et al. Detailed mapping of prostate carcinoma foci Biopsy strategy implications. Cancer. 89:2000;1800-1809
5. Frimmel H., Egevad L., Bengtsson E., Busch C. Modelling prostate cancer distributions. Urology. 54:1999;1028-1034
6. Wang J.Z., Guerrero M., Li X.A. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys. 55:2003;194-203
7. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101
8. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumours show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13
9. D'Souza W.D., Thames H.D. Is the α/β ratio for prostate cancer low? Int J Radiat Oncol Biol Phys. 51:2001;1-3
10. Duchesne G.M., Peters L.J. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 44:1999;747-748
11. Fowler J., Chappell R., Ritter M. Is α/β for prostate tumours really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031
12. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 51:2001;213-214
13. King C., Mayo C.S. Is the prostate α/β ratio of 1.5 from Brenner & Hall a modelling artefact? Int J Radiat Oncol Biol Phys. 47:2000;536-538
14. Lindsay P.E., Moiseenko V.V., Van Dyk J., Battista J.J. The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer. Phys Med Biol. 48:2003;507-522
15. Fowler J.F., Chappell R.J. How low is the α/β ratio for prostate cancer? In regard to Wang, et al. Int J Radiat Oncol Biol Phys. 57:2003;593-595
16. Wang J.Z., Guerrero M., Li X.A. Low α/β ratio for prostate cancer in response to Dr Fowler, et al. Int J Radiat Oncol Biol Phys. 57:2003;595-596
17. Haworth A., Ebert M., Joseph D., Kaye K. Registration of prostate volume with radiographically identified I-125 seeds for permanent implant evaluation. J Brachytherapy Int. 16:2000;157-167
18. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 22:1995;209-234
19. Ebert M., Zavgorodni S. Modelling dose-response in the presence of spatial variations in dose-rate. Med Phys. 27:2000;393-400
20. Dale R.G. Dose rate effects in targeted radiotherapy. Phys Med Biol. 41:1996;1871-1884
21. Webb S., Nahum A.E. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol. 38:1993;653-666
22. Webb S. Optimum parameters in a model for tumour control probability including interpatient heterogeneity. Phys Med Biol. 39:1994;1895-1914
23. Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer Implications for the α/β ratio. Int J Radiat Oncol Biol Phys. 57:2003;391-401
24. Sidhu S., Morris W.J., Spadinger I., et al. Prostate brachytherapy postimplant dosimetry a comparison of prostate quadrants. Int J Radiat Oncol Biol Phys. 52:2002;544-552
25. Bice W.S., Prestidge B.R., Sarosdy M.F. Sector analysis of prostate implants. Med Phys. 28:2001;2561-2567
26. Levegrun S., Jackson A., Zelefsky M.J., et al. Fitting of tumour control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer pitfalls in deducing radiobiological parameters for tumours from clinical data. Int J Radiat Oncol Biol Phys. 4:2001;1064-1080
27. Sanchez-Nieto B., Nahum A.E. The delta-TCP concept A clinically useful measure of tumour control probability. Int J Radiat Oncol Biol Phys. 44:1999;369-380
28. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin Oncol. 17:1999;517-522
29. 125I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;30-40